

Press Release

2nd Asian BioManufacturing Conference to be held from 3 to 4 December 2007

Advancing the biopharm industry in Asia through innovation, excellence in biomanufacturing and strategic partnerships

Putra Nilai, 14 November 2007 – Inno Biologics announced the 2nd Asian BioManufacturing Conference which will be held from 3 to 4 December 2007 at Sheraton Imperial Hotel, Kuala Lumpur. This event is organised in conjunction with the National Innovation Conference and Exhibition (NICE) as well as a post-conference of BioMalaysia 2007 (27 – 30 November 2007). The overall theme of the 2nd Asian BioManufacturing Conference is "Innovation & Excellence in Biomanufacturing".

These events combined are expected to attract industry leaders, innovators and business solution providers to Malaysia.

Y.Bhg Dato' Dr. Nazlee Kamal, CEO of Inno Biologics and Group Managing Director of Inno Bio Ventures Sdn Bhd said he is very pleased to announce the 2nd Asian BioManufacturing Conference. The first conference was held in 2005 and it was very successful. We hope to repeat our success with the 2nd Asian BioManufacturing Conference and so far we have received positive feedback from the key players in the industry.

"22 speakers have confirmed their participation in this event. The speakers are from various organisations such as Amgen, Alpha Biologics, Sartorius Stedim, Pfizer Global Biologics, Selexis, Pharmaniaga, Emergene AG and many others. We are expecting 250 participants from Asia-Pacific, US and EU this year", added Dr. Mohd. Nazlee.

The conference will address the scientific and technical matters such as expression systems, upstream and downstream processing, bio-product characterization, formulation, fill & finish of biologics and other key drivers, ancillary and supporting issues which are important to the biomanufacturing industry.

"We are determined to place an emphasis on Asian biomanufacturing industry and would like to provide an alternative platform for the Asian industry leaders to underline their capacity and enormous potential across the biopharmaceutical value chain. It is important for us to constantly having dialogues with the biopharmaceutical powerhouse such as those established players from the developed countries", added Dato' Dr. Nazlee.

The rise of the Asian biomanufacturing activities has also been exemplified by the recent contract clinched by Inno Biologics. Inno Biologics and Boehringer Ingelheim have entered into a 10-year cooperation agreement which Inno Biologics' clients will gain access to Boehringer Ingelheim's manufacturing

technology platform for biopharmaceutical products produced by mammalian cell culture.

The partnership will take advantage of the complementary strengths of both companies within the biomanufacturing area. Through this partnership, Inno Biologics will now offer its clients bioprocessing services using Boehringer Ingelheim's well established systems for various stages of process development and biomanufacturing for clinical Phase I and II. In the event where a client's pipeline product advances to Phase III clinical and beyond, Boehringer Ingelheim will be positioned as the preferred partner for large scale biomanufacturing for the same client, if desired by the client.

Today, sponsors for 2nd Asian BioManufacturing Conference include Pharmabiotech, Pall Life Sciences, Sartorius Stedim, GE Healthcare and NNE Pharmaplan. Inno Bio is still seeking more sponsors and participants.

Recognising that posters are a valuable resource to learn about the up and coming advances in the area of manufacturing, we are organising poster competition in conjunction with this conference. The poster competition is open to all universities, registered delegates of the conference and all academia in Malaysia. So far, we have received good feedback from universities and we look forward to have more participation in this competition.

For more information on the conference, please visit the official website at www.innobiologics.com/conference/.

About Inno Biologics

Inno Biologics Sdn. Bhd. is the key company of Inno Bio Ventures Sdn. Bhd., a Malaysian Ministry of Finance Incorporated Company with a close affiliation with Ministry of Science, Technology and Innovation of Malaysia.

Inno Biologics' services encompass gene cloning and expression using mammalian cell expression system; bioprocess development and cGMP biopharmaceutical manufacturing.

Inno Biologics provides biopharmaceutical manufacturing services to local and international bio pharmaceutical companies. Its world class cGMP facility is built to conform to US FDA, EMEA and PIC/S regulations.

As a company awarded with BioNexus Status, Inno Biologics enjoys 100% income tax exemption for 10 years commencing from the first year the company derives profit.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For further information, please contact:

Soheir Khatib
Vice President,
Corporate Strategy
Inno Bio Ventures Sdn. Bhd.
Phone: +606 799 6661 or +606 799 6662
Fax: +606 799 6660
E-mail: soheir.khatib@innobioventures.com